Microbot Medical Inc. filed a definitive proxy statement on November 3, 2026, notifying shareholders of its 2026 Annual Meeting to be held on December 14, 2026, at 9:00 A.M. Eastern Time in Boston, Massachusetts.

Key Highlights

  • Annual Meeting date: December 14, 2026, at the offices of Nixon Peabody LLP, 53 State Street, Boston, MA 02109.
  • Record date: The Board fixed the close of business on October 15, 2026, as the record date; 67,164,801 shares of common stock were outstanding on that date.
  • Director election: Shareholders are asked to elect two Class II directors to serve until the 2029 Annual Meeting of Shareholders.
  • Equity plan amendment: Proposal 3 seeks approval to increase shares reserved under the 2020 Omnibus Performance Award Plan by 1,000,000 shares.
  • Auditor ratification: Shareholders are asked to ratify Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, as independent auditor for the year ending December 31, 2026.
  • Proxy solicitor cost: The company retained Sodali & Co. LLC at an estimated cost of $13,000 plus expenses.

Microbot Medical's 2026 Proxy Proposals and Voting Details

According to the definitive proxy statement, Microbot Medical Inc. (NASDAQ:MBOT) is soliciting proxies for its 2026 Annual Meeting of Shareholders. The Board of Directors has set October 15, 2026 as the record date, at which time 67,164,801 shares of common stock, each carrying one vote, were outstanding. The proxy materials were first made available on or about November 2, 2026.

The filing describes four proposals on which shareholders will vote. Proposal 1 calls for the election of two Class II directors to serve until the 2029 Annual Meeting. Proposal 2 asks for a non-binding advisory vote on the compensation of the company's named executive officers. Proposal 3 requests approval of an amendment to the Microbot Medical Inc. 2020 Omnibus Performance Award Plan to increase the number of authorized shares of common stock reserved for issuance by 1,000,000 shares. Proposal 4 covers the ratification of Brightman Almagor Zohar & Co., a Member of Deloitte Touche Tohmatsu Limited, or its U.S. affiliate, as the company's independent registered public accounting firm for the year ending December 31, 2026. The Board recommends a "FOR" vote on all four proposals, according to the filing.

The company disclosed that it will bear the full cost of proxy solicitation, including printing and filing costs, and has retained Sodali & Co. LLC as proxy solicitor at an estimated cost of $13,000 plus expenses. Directors, officers, and employees may also solicit proxies by telephone, email, facsimile, or in person for no additional compensation, the filing states. Shareholders who vote by proxy retain the right to attend the meeting and vote their shares in person. The proxy statement was signed by Harel Gadot, Chairman, President and Chief Executive Officer, and dated November 2, 2026.

What Was Disclosed

Microbot Medical filed a definitive proxy statement covering four shareholder proposals for its December 14, 2026 Annual Meeting, including a director election, a say-on-pay vote, an equity plan share increase of 1,000,000 shares, and auditor ratification, with 67,164,801 shares eligible to vote.